0000904454-18-000329.txt : 20180502
0000904454-18-000329.hdr.sgml : 20180502
20180502162901
ACCESSION NUMBER: 0000904454-18-000329
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180430
FILED AS OF DATE: 20180502
DATE AS OF CHANGE: 20180502
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoffmann Rolf K
CENTRAL INDEX KEY: 0001737142
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36066
FILM NUMBER: 18800042
MAIL ADDRESS:
STREET 1: LORBEERWEG 7
CITY: WEGGIS
STATE: V8
ZIP: CH-6353
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001178711
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330960223
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 PARK PLAZA
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: (617) 807-6600
MAIL ADDRESS:
STREET 1: 75 PARK PLAZA
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc
DATE OF NAME CHANGE: 20090130
FORMER COMPANY:
FORMER CONFORMED NAME: NOVACEA INC
DATE OF NAME CHANGE: 20020724
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-04-30
0001178711
Paratek Pharmaceuticals, Inc.
PRTK
0001737142
Hoffmann Rolf K
C/O PARATEK PHARMACEUTICALS, INC.
75 PARK PLAZA, 4TH FLOOR
BOSTON
MA
02116
1
0
0
0
Common Stock
2018-04-30
4
A
0
15000
0
A
18500
D
Stock Option (right to buy)
10.70
2018-04-30
4
A
0
10000
0
A
2028-04-30
Common Stock
10000
10000
D
Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on April 30, 2019, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date.
The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant.
The stock option was granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. The stock option shall vest as to 1/36 of the shares on May 31, 2018, and on the last day of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date.
/s/ William M. Haskel, Attorney-in-Fact for Rolf K. Hoffmann
2018-05-02